Lucid Diagnostics Inc. has announced an underwritten public offering of 25 million shares of common stock at $1.00 per share, priced on September 10, 2025, with gross proceeds expected to be $25 million. Additionally, the underwriters have the option to purchase up to 3.75 million more shares within 30 days at the same price, bringing total potential gross proceeds to $28.75 million.